KelSie Biotech

Executive Summary

KelSie Biotech is a private biotechnology firm founded in 2018, headquartered in Boulder, Colorado, with operations in Cambridge, Massachusetts. The company specializes in drug delivery using its proprietary Carbon-Dioxide Assisted Nebulization Bubble Drying (CAN-BD) technology, which enables the creation of dry powder inhalable and sublingual formulations for small molecule therapeutics. Its primary focus areas are oncology and inflammatory diseases, aiming to improve the bioavailability and patient compliance of existing drugs. KelSie's platform offers a differentiated approach to reformulating drugs with poor oral bioavailability or those requiring injection, potentially expanding market access and reducing side effects.

Upcoming Catalysts (preview)

• Q2 2027Initiation of Phase 1 Clinical Trial for Lead Candidate40% success
• Q4 2026Strategic Licensing or Co-Development Agreement with Major Pharma35% success
• Q3 2026Award of SBIR/STTR Grant or Non-Dilutive Funding50% success